热针可确认[18F]PSMA-1007 PET/CT引导活检术中病灶取样准确性用于疑似前列腺癌患者
这项前瞻性概念验证研究纳入5例疑似前列腺癌患者,行[18F]PSMA-1007 PET/CT后立即行PET/CT引导及饱和模板活检,用伽马谱仪测量活检针芯放射性计数。113针中43针有前列腺癌,有癌针芯平均计数263±396 cpm高于无癌针芯73±44 cpm(p<0.001);排除1例中度PSMA摄取患者后ROC分析AUC为0.81,确认前列腺癌最佳阈值为75 cpm(敏感度65.1%、特异度87%)。作者认为该技术可术中确认优势肿瘤取样准确性,可能减少饱和活检需求。
要点
- 有前列腺癌针芯平均计数263±396 cpm,高于无癌针芯73±44 cpm(p<0.001)。
- 排除1例中度摄取患者后,ROC分析AUC为0.81,确认前列腺癌最佳阈值为75 cpm(敏感度65.1%、特异度87%)。
- 4例前列腺癌患者中,第一或第二针PSMA PET引导针均阳性且计数高(156-2079 cpm)。
核心结论
- 前列腺癌中[18F]PSMA-1007摄取可用于术中确认优势肿瘤病灶取样准确性。
- 该技术可能提高影像引导活检的信心并减少饱和活检需求。
研究设计与样本
- IRB批准的前瞻性概念验证研究,纳入5例连续疑似前列腺癌患者。
- 所有患者行[18F]PSMA-1007 PET/CT后立即(PET后3.1±0.3 h)行PET/CT引导及饱和模板活检。
- 活检针芯放射性以伽马谱仪测量每分钟计数(cpm),用Pearson检验与组织病理(WHO/ISUP)、肿瘤长度及免疫组化膜性PSMA表达做相关分析。
- 试验注册号NCT03187990,注册日期2017年6月15日。
主要发现
- 113针中43针存在前列腺癌。
- 有前列腺癌针芯平均计数263±396 cpm,高于无前列腺癌针芯73±44 cpm(p<0.001)。
- 1例中度PSMA摄取患者(SUVmax 8.7)24针中13针计数升高(100-200 cpm),但免疫组化仅见炎症及良性腺体PSMA表达。
- 排除该病例后ROC分析AUC为0.81,确认前列腺癌最佳阈值为75 cpm,敏感度65.1%、特异度87%。
- 4例前列腺癌患者中第一或第二针PSMA PET引导针均阳性且计数高(156-2079 cpm)。
关键数值与推荐
- 术中确认前列腺癌的最佳计数阈值为75 cpm(排除1例中度摄取患者后,敏感度65.1%、特异度87%,AUC 0.81)。
临床怎么用
- 作者认为该技术可术中确认优势肿瘤取样准确性,可能提高影像引导活检信心并减少饱和活检需求。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted PET is increasingly used for staging prostate cancer (PCa) with high accuracy to detect significant PCa (sigPCa). [68 Ga]PSMA-11 PET/MRI-guided biopsy showed promising results but also persisting limitation of sampling error, due to impaired image fusion. We aimed to assess the possibility of intraoperative quantification of [18F]PSMA-1007 PET/CT uptake in core biopsies as an instant confirmation for accurate lesion sampling. METHODS: In this IRB-approved, prospective, proof-of-concept study, we included five consecutive patients with suspected PCa. All underwent [18F]PSMA-1007 PET/CT scans followed by immediate PET/CT-guided and saturation template biopsy (3.1 ± 0.3 h after PET). The activity in biopsy cores was measured as counts per minute (cpm) in a gamma spectrometer. Pearson's test was used to correlate counts with histopathology (WHO/ISUP), tumor length, and membranous PSMA expression on immunohistochemistry (IHC). RESULTS: In 43 of 113 needles, PCa was present. The mean cpm was overall significantly higher in needles with PCa (263 ± 396 cpm) compared to needles without PCa (73 ± 44 cpm, p < 0.001). In one patient with moderate PSMA uptake (SUVmax 8.7), 13 out of 24 needles had increased counts (100-200 cpm) but only signs of inflammation and PSMA expression in benign glands on IHC. Excluding this case, ROC analysis resulted in an AUC of 0.81, with an optimal cut-off to confirm PCa at 75 cpm (sens/spec of 65.1%/87%). In all 4 patients with PCa, the first or second PSMA PET-guided needle was positive for sigPCa with high counts (156-2079 cpm). CONCLUSIONS: [18F]PSMA-1007 uptake in PCa can be used to confirm accurate lesion sampling of the dominant tumor intraoperatively. This technique could improve confidence in imaging-based biopsy guidance and reduce the need for saturation biopsy. TRIAL REGISTRATION NUMBER: NCT03187990, 15/06/2017.
引用
- Ferraro DA, Laudicella R, Zeimpekis K, et al. Hot needles can confirm accurate lesion sampling intraoperatively using [18F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34725726. doi:10.1007/s00259-021-05599-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。